Circulating T cells to infliximab are detectable mainly in treated patients developing anti‐drug antibodies and hypersensitivity reactions
Summary Antibodies recognizing infliximab (IFX) may develop in a proportion of treated patients, leading to loss of response or hypersensitivity reactions (HRs). T cell response to IFX has been poorly investigated. This paper was addressed to detect IFX‐specific T cells in treated patients with infl...
Saved in:
| Published in | Clinical and experimental immunology Vol. 186; no. 3; pp. 364 - 372 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Oxford University Press
01.12.2016
John Wiley and Sons Inc |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Summary
Antibodies recognizing infliximab (IFX) may develop in a proportion of treated patients, leading to loss of response or hypersensitivity reactions (HRs). T cell response to IFX has been poorly investigated. This paper was addressed to detect IFX‐specific T cells in treated patients with inflammatory diseases developing, or not, anti‐drug antibodies (ADA) and to correlate the presence of specific T cells with the clinical outcomes of the treatment. A co‐culture system of IFX‐loaded dendritic cells and purified autologous CD4+ T cells was used to detect memory T cells in 32 ADA+ and 39 ADA– IFX‐treated patients and control groups. The cytokine profile of IFX‐specific T cells was also studied in culture supernatants. IFX‐specific cell proliferation was detected mainly in cells from ADA+ patients, irrespective of their different diseases. HR patients displayed higher T cell proliferation than non‐responder and tolerant patients. A mixed [interferon (IFN)‐γ, interleukin (IL)‐13, IL‐10] cytokine profile was shown in cells from ADA+ patients, while IL‐10 was the most frequently detected cytokine in the supernatants of cultures from ADA‐ patients. Immunoglobulin (Ig)E+ADA+ patients with previous HRs exhibited a more pronounced type 2 profile than IgE–ADA+ patients. This work provides evidence that IFX‐specific circulating T cells are detectable mainly in ADA+ patients with HRs, regardless of their disease. The IFX‐induced cytokine pattern partially correlates with the ADA isotype.
T cell response to IFX is detectable in a proportion of treated patients, mainly in ADA+ patients who displayed an immediate hypersensitivity reaction
The cytokine profile partially correlates with the clinical outcome of the treatment
Proliferation assay combined with cyokines evaluation may work better than the single test in evaluating cell sensitization |
|---|---|
| AbstractList | Summary Antibodies recognizing infliximab (IFX) may develop in a proportion of treated patients, leading to loss of response or hypersensitivity reactions (HRs). T cell response to IFX has been poorly investigated. This paper was addressed to detect IFX-specific T cells in treated patients with inflammatory diseases developing, or not, anti-drug antibodies (ADA) and to correlate the presence of specific T cells with the clinical outcomes of the treatment. A co-culture system of IFX-loaded dendritic cells and purified autologous CD4+ T cells was used to detect memory T cells in 32 ADA+ and 39 ADA- IFX-treated patients and control groups. The cytokine profile of IFX-specific T cells was also studied in culture supernatants. IFX-specific cell proliferation was detected mainly in cells from ADA+ patients, irrespective of their different diseases. HR patients displayed higher T cell proliferation than non-responder and tolerant patients. A mixed [interferon (IFN)-[gamma], interleukin (IL)-13, IL-10] cytokine profile was shown in cells from ADA+ patients, while IL-10 was the most frequently detected cytokine in the supernatants of cultures from ADA- patients. Immunoglobulin (Ig)E+ADA+ patients with previous HRs exhibited a more pronounced type 2 profile than IgE-ADA+ patients. This work provides evidence that IFX-specific circulating T cells are detectable mainly in ADA+ patients with HRs, regardless of their disease. The IFX-induced cytokine pattern partially correlates with the ADA isotype. Antibodies recognizing infliximab (IFX) may develop in a proportion of treated patients, leading to loss of response or hypersensitivity reactions (HRs). T cell response to IFX has been poorly investigated. This paper was addressed to detect IFX‐specific T cells in treated patients with inflammatory diseases developing, or not, anti‐drug antibodies (ADA) and to correlate the presence of specific T cells with the clinical outcomes of the treatment. A co‐culture system of IFX‐loaded dendritic cells and purified autologous CD4 + T cells was used to detect memory T cells in 32 ADA + and 39 ADA – IFX‐treated patients and control groups. The cytokine profile of IFX‐specific T cells was also studied in culture supernatants. IFX‐specific cell proliferation was detected mainly in cells from ADA + patients, irrespective of their different diseases. HR patients displayed higher T cell proliferation than non‐responder and tolerant patients. A mixed [interferon (IFN)‐γ, interleukin (IL)‐13, IL‐10] cytokine profile was shown in cells from ADA + patients, while IL‐10 was the most frequently detected cytokine in the supernatants of cultures from ADA‐ patients. Immunoglobulin (Ig)E + ADA + patients with previous HRs exhibited a more pronounced type 2 profile than IgE – ADA + patients. This work provides evidence that IFX‐specific circulating T cells are detectable mainly in ADA + patients with HRs, regardless of their disease. The IFX‐induced cytokine pattern partially correlates with the ADA isotype. Antibodies recognizing infliximab (IFX) may develop in a proportion of treated patients, leading to loss of response or hypersensitivity reactions (HRs). T cell response to IFX has been poorly investigated. This paper was addressed to detect IFX-specific T cells in treated patients with inflammatory diseases developing, or not, anti-drug antibodies (ADA) and to correlate the presence of specific T cells with the clinical outcomes of the treatment. A co-culture system of IFX-loaded dendritic cells and purified autologous CD4 T cells was used to detect memory T cells in 32 ADA and 39 ADA IFX-treated patients and control groups. The cytokine profile of IFX-specific T cells was also studied in culture supernatants. IFX-specific cell proliferation was detected mainly in cells from ADA patients, irrespective of their different diseases. HR patients displayed higher T cell proliferation than non-responder and tolerant patients. A mixed [interferon (IFN)-γ, interleukin (IL)-13, IL-10] cytokine profile was shown in cells from ADA patients, while IL-10 was the most frequently detected cytokine in the supernatants of cultures from ADA- patients. Immunoglobulin (Ig)E ADA patients with previous HRs exhibited a more pronounced type 2 profile than IgE ADA patients. This work provides evidence that IFX-specific circulating T cells are detectable mainly in ADA patients with HRs, regardless of their disease. The IFX-induced cytokine pattern partially correlates with the ADA isotype. Summary Antibodies recognizing infliximab (IFX) may develop in a proportion of treated patients, leading to loss of response or hypersensitivity reactions (HRs). T cell response to IFX has been poorly investigated. This paper was addressed to detect IFX‐specific T cells in treated patients with inflammatory diseases developing, or not, anti‐drug antibodies (ADA) and to correlate the presence of specific T cells with the clinical outcomes of the treatment. A co‐culture system of IFX‐loaded dendritic cells and purified autologous CD4+ T cells was used to detect memory T cells in 32 ADA+ and 39 ADA– IFX‐treated patients and control groups. The cytokine profile of IFX‐specific T cells was also studied in culture supernatants. IFX‐specific cell proliferation was detected mainly in cells from ADA+ patients, irrespective of their different diseases. HR patients displayed higher T cell proliferation than non‐responder and tolerant patients. A mixed [interferon (IFN)‐γ, interleukin (IL)‐13, IL‐10] cytokine profile was shown in cells from ADA+ patients, while IL‐10 was the most frequently detected cytokine in the supernatants of cultures from ADA‐ patients. Immunoglobulin (Ig)E+ADA+ patients with previous HRs exhibited a more pronounced type 2 profile than IgE–ADA+ patients. This work provides evidence that IFX‐specific circulating T cells are detectable mainly in ADA+ patients with HRs, regardless of their disease. The IFX‐induced cytokine pattern partially correlates with the ADA isotype. T cell response to IFX is detectable in a proportion of treated patients, mainly in ADA+ patients who displayed an immediate hypersensitivity reaction The cytokine profile partially correlates with the clinical outcome of the treatment Proliferation assay combined with cyokines evaluation may work better than the single test in evaluating cell sensitization Antibodies recognizing infliximab (IFX) may develop in a proportion of treated patients, leading to loss of response or hypersensitivity reactions (HRs). T cell response to IFX has been poorly investigated. This paper was addressed to detect IFX-specific T cells in treated patients with inflammatory diseases developing, or not, anti-drug antibodies (ADA) and to correlate the presence of specific T cells with the clinical outcomes of the treatment. A co-culture system of IFX-loaded dendritic cells and purified autologous CD4+ T cells was used to detect memory T cells in 32 ADA+ and 39 ADA- IFX-treated patients and control groups. The cytokine profile of IFX-specific T cells was also studied in culture supernatants. IFX-specific cell proliferation was detected mainly in cells from ADA+ patients, irrespective of their different diseases. HR patients displayed higher T cell proliferation than non-responder and tolerant patients. A mixed [interferon (IFN)-γ, interleukin (IL)-13, IL-10] cytokine profile was shown in cells from ADA+ patients, while IL-10 was the most frequently detected cytokine in the supernatants of cultures from ADA- patients. Immunoglobulin (Ig)E+ ADA+ patients with previous HRs exhibited a more pronounced type 2 profile than IgE- ADA+ patients. This work provides evidence that IFX-specific circulating T cells are detectable mainly in ADA+ patients with HRs, regardless of their disease. The IFX-induced cytokine pattern partially correlates with the ADA isotype.Antibodies recognizing infliximab (IFX) may develop in a proportion of treated patients, leading to loss of response or hypersensitivity reactions (HRs). T cell response to IFX has been poorly investigated. This paper was addressed to detect IFX-specific T cells in treated patients with inflammatory diseases developing, or not, anti-drug antibodies (ADA) and to correlate the presence of specific T cells with the clinical outcomes of the treatment. A co-culture system of IFX-loaded dendritic cells and purified autologous CD4+ T cells was used to detect memory T cells in 32 ADA+ and 39 ADA- IFX-treated patients and control groups. The cytokine profile of IFX-specific T cells was also studied in culture supernatants. IFX-specific cell proliferation was detected mainly in cells from ADA+ patients, irrespective of their different diseases. HR patients displayed higher T cell proliferation than non-responder and tolerant patients. A mixed [interferon (IFN)-γ, interleukin (IL)-13, IL-10] cytokine profile was shown in cells from ADA+ patients, while IL-10 was the most frequently detected cytokine in the supernatants of cultures from ADA- patients. Immunoglobulin (Ig)E+ ADA+ patients with previous HRs exhibited a more pronounced type 2 profile than IgE- ADA+ patients. This work provides evidence that IFX-specific circulating T cells are detectable mainly in ADA+ patients with HRs, regardless of their disease. The IFX-induced cytokine pattern partially correlates with the ADA isotype. Antibodies recognizing infliximab (IFX) may develop in a proportion of treated patients, leading to loss of response or hypersensitivity reactions (HRs). T cell response to IFX has been poorly investigated. This paper was addressed to detect IFX-specific T cells in treated patients with inflammatory diseases developing, or not, anti-drug antibodies (ADA) and to correlate the presence of specific T cells with the clinical outcomes of the treatment. A co-culture system of IFX-loaded dendritic cells and purified autologous CD4+ T cells was used to detect memory T cells in 32 ADA+ and 39 ADA– IFX-treated patients and control groups. The cytokine profile of IFX-specific T cells was also studied in culture supernatants. IFX-specific cell proliferation was detected mainly in cells from ADA+ patients, irrespective of their different diseases. HR patients displayed higher T cell proliferation than non-responder and tolerant patients. A mixed [interferon (IFN)-γ, interleukin (IL)-13, IL-10] cytokine profile was shown in cells from ADA+ patients, while IL-10 was the most frequently detected cytokine in the supernatants of cultures from ADA- patients. Immunoglobulin (Ig)E+ADA+ patients with previous HRs exhibited a more pronounced type 2 profile than IgE–ADA+ patients. This work provides evidence that IFX-specific circulating T cells are detectable mainly in ADA+ patients with HRs, regardless of their disease. The IFX-induced cytokine pattern partially correlates with the ADA isotype. Antibodies recognizing infliximab (IFX) may develop in a proportion of treated patients, leading to loss of response or hypersensitivity reactions (HRs). T cell response to IFX has been poorly investigated. This paper was addressed to detect IFX-specific T cells in treated patients with inflammatory diseases developing, or not, anti-drug antibodies (ADA) and to correlate the presence of specific T cells with the clinical outcomes of the treatment. A co-culture system of IFX-loaded dendritic cells and purified autologous CD4 super(+) T cells was used to detect memory T cells in 32 ADA super(+) and 39 ADA super(-) IFX-treated patients and control groups. The cytokine profile of IFX-specific T cells was also studied in culture supernatants. IFX-specific cell proliferation was detected mainly in cells from ADA super(+) patients, irrespective of their different diseases. HR patients displayed higher T cell proliferation than non-responder and tolerant patients. A mixed [interferon (IFN)- gamma , interleukin (IL)-13, IL-10] cytokine profile was shown in cells from ADA super(+) patients, while IL-10 was the most frequently detected cytokine in the supernatants of cultures from ADA- patients. Immunoglobulin (Ig)E super(+)ADA super(+) patients with previous HRs exhibited a more pronounced type 2 profile than IgE super(-)ADA super(+) patients. This work provides evidence that IFX-specific circulating T cells are detectable mainly in ADA super(+) patients with HRs, regardless of their disease. The IFX-induced cytokine pattern partially correlates with the ADA isotype. * T cell response to IFX is detectable in a proportion of treated patients, mainly in ADA+ patients who displayed an immediate hypersensitivity reaction * The cytokine profile partially correlates with the clinical outcome of the treatment * Proliferation assay combined with cyokines evaluation may work better than the single test in evaluating cell sensitization |
| Author | Milla, M. Pratesi, S. Prignano, F. Nencini, F. Annese, V. Romagnani, S. Maggi, E. Matucci, A. Vultaggio, A. Petroni, G. Cammelli, D. |
| AuthorAffiliation | 1 Centre of Research DENOTHE and Department of Experimental and Clinical Medicine University of Florence Italy 4 Dermatology Clinic, Azienda Sanitaria Firenze, Department of Surgery and Translational Medicine University of Florence Florence Italy 3 Gastroenterology Unit Azienda Ospedaliero‐Universitaria Careggi Florence Italy 2 Immunoallergology Unit Azienda Ospedaliero‐Universitaria Careggi Florence Italy |
| AuthorAffiliation_xml | – name: 4 Dermatology Clinic, Azienda Sanitaria Firenze, Department of Surgery and Translational Medicine University of Florence Florence Italy – name: 1 Centre of Research DENOTHE and Department of Experimental and Clinical Medicine University of Florence Italy – name: 2 Immunoallergology Unit Azienda Ospedaliero‐Universitaria Careggi Florence Italy – name: 3 Gastroenterology Unit Azienda Ospedaliero‐Universitaria Careggi Florence Italy |
| Author_xml | – sequence: 1 givenname: A. surname: Vultaggio fullname: Vultaggio, A. organization: Azienda Ospedaliero‐Universitaria Careggi – sequence: 2 givenname: G. surname: Petroni fullname: Petroni, G. organization: University of Florence – sequence: 3 givenname: S. surname: Pratesi fullname: Pratesi, S. organization: University of Florence – sequence: 4 givenname: F. surname: Nencini fullname: Nencini, F. organization: University of Florence – sequence: 5 givenname: D. surname: Cammelli fullname: Cammelli, D. organization: Azienda Ospedaliero‐Universitaria Careggi – sequence: 6 givenname: M. surname: Milla fullname: Milla, M. organization: Azienda Ospedaliero‐Universitaria Careggi – sequence: 7 givenname: F. surname: Prignano fullname: Prignano, F. organization: University of Florence – sequence: 8 givenname: V. surname: Annese fullname: Annese, V. organization: Azienda Ospedaliero‐Universitaria Careggi – sequence: 9 givenname: S. surname: Romagnani fullname: Romagnani, S. organization: University of Florence – sequence: 10 givenname: E. surname: Maggi fullname: Maggi, E. email: enrico.maggi@unifi.it organization: University of Florence – sequence: 11 givenname: A. surname: Matucci fullname: Matucci, A. organization: Azienda Ospedaliero‐Universitaria Careggi |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27569750$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNksFu1DAQhi1URLeFAy-ALHGBQ1o7cRzngoRWBSpV4lLOluNMWldeO9jOQm48AIc-Y58Eh90iqEDCF8_I3_9rZjxH6MB5Bwg9p-SE5nOqwZzQUtTiEVrRitdFWbL2AK0IIW3RUsIO0VGMNznlnJdP0GHZ1LxtarJC39cm6MmqZNwVvsQarI04eWzcYM1Xs1EdVgFwDwl0Up0FvFHG2TkDOAVQCXo8ZjW4FDO1BevHxUq5ZO6-3fZh2sWd7w3EHPb4eh4hRHDRJLM1acbZRifjXXyKHg_KRni2v4_Rp3dnl-sPxcXH9-frtxeFZg0XBahKVXTo-65qFde0BU1VVbcdEw0ZGl2TdtBq4KUgahhapgljvRaMqCYzNVTH6M3Od5y6DfQ6Fx-UlWPI_YZZemXkny_OXMsrv5U1JYI0JBu82hsE_3mCmOTGxGV2yoGfoqSCcUYbXlb_gVY1F6StRUZfPkBv_BRcnsRCNYxQ0bBMvfi9-F9V3_9pBk53gA4-xgCD1CapZcC5F2MlJXLZGpm3Rv7cmqx4_UBxb_o3du_-xViY_w3K9dn5TvEDiDbVyg |
| CitedBy_id | crossref_primary_10_1111_all_13471 crossref_primary_10_3390_ijms18102127 crossref_primary_10_1038_s41598_021_91851_7 crossref_primary_10_3389_fimmu_2020_01550 crossref_primary_10_1007_s12247_019_09412_5 crossref_primary_10_1016_j_jaci_2020_11_012 crossref_primary_10_1111_all_14984 crossref_primary_10_3389_fimmu_2020_01951 crossref_primary_10_1097_ACI_0000000000000666 crossref_primary_10_1016_j_xphs_2022_01_032 crossref_primary_10_2147_ITT_S477841 crossref_primary_10_3389_fimmu_2017_00500 crossref_primary_10_3389_fonc_2024_1346502 crossref_primary_10_1080_19420862_2024_2333729 crossref_primary_10_1016_j_prp_2024_155627 crossref_primary_10_3389_fphar_2024_1360835 crossref_primary_10_1080_17512433_2020_1772053 crossref_primary_10_1002_eji_202250340 crossref_primary_10_1080_17474124_2018_1494573 crossref_primary_10_4049_jimmunol_1700008 crossref_primary_10_3389_fimmu_2020_00312 crossref_primary_10_3389_fimmu_2023_1237754 crossref_primary_10_3389_fimmu_2024_1406643 crossref_primary_10_1016_j_ejpb_2018_06_008 crossref_primary_10_3389_fimmu_2020_01301 crossref_primary_10_1016_j_jaut_2017_10_003 crossref_primary_10_3389_fimmu_2018_03113 crossref_primary_10_1208_s12248_018_0194_9 crossref_primary_10_1080_14712598_2022_2142039 crossref_primary_10_1016_j_ejps_2023_106670 crossref_primary_10_1016_j_jaip_2016_12_001 crossref_primary_10_1080_1744666X_2020_1684264 |
| Cites_doi | 10.1053/j.gastro.2010.10.008 10.1038/nrrheum.2013.4 10.1093/rheumatology/keq031 10.1016/j.berh.2014.10.019 10.1136/gut.2009.201533 10.1111/cea.12098 10.2165/00003495-200565150-00014 10.1016/S0140-6736(80)92767-1 10.1159/000336839 10.3899/jrheum.091464 10.1136/ard.2009.110502 10.1016/j.jaci.2004.04.029 10.1016/j.jpba.2008.09.020 10.1002/ibd.20520 10.1016/j.cyto.2008.11.008 10.1586/eci.10.90 10.1002/art.23200 10.1016/j.clim.2014.02.008 10.1016/j.trsl.2014.09.006 10.1136/ard.62.9.817 10.1111/j.1398-9995.2009.02280.x 10.1053/j.gastro.2004.11.060 10.1096/fj.10-173872 10.1136/ard.2008.101279 10.1038/ncomms4199 10.1002/art.23447 |
| ContentType | Journal Article |
| Copyright | 2016 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for Immunology 2016 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for Immunology. 2016 British Society for Immunology |
| Copyright_xml | – notice: 2016 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for Immunology – notice: 2016 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for Immunology. – notice: 2016 British Society for Immunology |
| CorporateAuthor | on behalf of the ABIRISK Consortium ABIRISK Consortium |
| CorporateAuthor_xml | – name: on behalf of the ABIRISK Consortium – name: ABIRISK Consortium |
| DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7U9 H94 M7N 7X8 5PM |
| DOI | 10.1111/cei.12858 |
| DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts Virology and AIDS Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE MEDLINE - Academic CrossRef AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| DocumentTitleAlternate | IFX‐specific T cells in exposed subjects |
| EISSN | 1365-2249 |
| EndPage | 372 |
| ExternalDocumentID | PMC5108070 4243614831 27569750 10_1111_cei_12858 CEI12858 |
| Genre | article Journal Article |
| GrantInformation_xml | – fundername: Innovative Medicines Initiative |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 169 1OC 24P 29B 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 5WD 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 A8Z AABZA AACZT AAESR AAEVG AAHHS AAONW AAPXW AARHZ AAUAY AAVAP AAZKR ABCQN ABCUV ABDBF ABDFA ABEJV ABEML ABJNI ABLJU ABNHQ ABOCM ABPTD ABPVW ABQNK ABXVV ACAHQ ACCFJ ACFBH ACGFO ACGFS ACMXC ACPOU ACPRK ACSCC ACUFI ACUHS ACXQS ADBBV ADEOM ADIPN ADIYS ADIZJ ADKYN ADMGS ADOZA ADQBN ADVEK ADXAS ADZMN ADZOD AEEZP AEGXH AEIMD AENEX AEQDE AEUQT AFBPY AFEBI AFFZL AFGKR AFPWT AFRAH AFTUV AFXAL AFZJQ AGMDO AGUTN AHMMS AIACR AIAGR AIURR AIWBW AJAOE AJBDE AJEEA ALAGY ALMA_UNASSIGNED_HOLDINGS AMBMR AMYDB AOIJS ATGXG ATUGU AZBYB AZVAB BAFTC BAWUL BCRHZ BEYMZ BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EAS EBB EBC EBD EBS EBX EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FIJ FUBAC G-S G.N GODZA GX1 H.X H13 HF~ HZI HZ~ IH2 IHE IPNFZ IX1 J0M J5H K48 KBUDW KBYEO KOP KSI KSN LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NOMLY NU- O66 O9- OAUYM OBS OCZFY OHT OIG OJZSN OK1 OPAEJ OVD OWPYF P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 Q~Q R.K ROL ROX RPM RX1 SUPJJ SV3 TEORI TR2 TUS UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOQ WOW WQJ WRC WVDHM WXI X7M XG1 Y6R YFH YOC YUY ZGI ZXP ZZTAW ~IA ~KM ~WT AAFWJ AAYXX ABGNP ABVGC AEMQT AGORE AJBYB AJNCP ALXQX CITATION ACVCV AFFQV AJDVS CGR CUY CVF ECM EIF NPM 7T5 7U9 AAMMB AEFGJ AGXDD AIDQK AIDYY H94 M7N 7X8 5PM |
| ID | FETCH-LOGICAL-c4768-ea3a31fddb39a6c19ec1a359b4870f7c509fcaf6280aff94c044dc840a79b45e3 |
| IEDL.DBID | DR2 |
| ISSN | 0009-9104 1365-2249 |
| IngestDate | Thu Aug 21 14:06:31 EDT 2025 Tue Aug 05 10:10:38 EDT 2025 Fri Jul 11 00:42:55 EDT 2025 Wed Aug 13 10:52:21 EDT 2025 Thu Apr 03 06:54:54 EDT 2025 Tue Jul 01 03:52:47 EDT 2025 Thu Apr 24 22:53:46 EDT 2025 Wed Jan 22 16:41:19 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | allergy cytokines arthritis T cells |
| Language | English |
| License | Attribution-NonCommercial-NoDerivs https://creativecommons.org/licenses/by-nc-nd/4.0 2016 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for Immunology. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4768-ea3a31fddb39a6c19ec1a359b4870f7c509fcaf6280aff94c044dc840a79b45e3 |
| Notes | AV and GP contributed equally to the paper. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcei.12858 |
| PMID | 27569750 |
| PQID | 1837401874 |
| PQPubID | 36527 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5108070 proquest_miscellaneous_1846417623 proquest_miscellaneous_1835680958 proquest_journals_1837401874 pubmed_primary_27569750 crossref_citationtrail_10_1111_cei_12858 crossref_primary_10_1111_cei_12858 wiley_primary_10_1111_cei_12858_CEI12858 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | December 2016 |
| PublicationDateYYYYMMDD | 2016-12-01 |
| PublicationDate_xml | – month: 12 year: 2016 text: December 2016 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Oxford – name: Hoboken |
| PublicationTitle | Clinical and experimental immunology |
| PublicationTitleAlternate | Clin Exp Immunol |
| PublicationYear | 2016 |
| Publisher | Oxford University Press John Wiley and Sons Inc |
| Publisher_xml | – name: Oxford University Press – name: John Wiley and Sons Inc |
| References | 2009; 45 2009; 68 2013; 43 2011; 60 2015; 165 2008; 58 2008; 14 2005; 65 2014; 151 2014; 28 2010; 85 2005; 23 2011; 7 2013; 9 2010; 65 2010; 49 2014; 5 2004; 114 2010; 69 1980; 1 2005; 128 2008; 48 2011; 25 2012; 159 2011; 140 2003; 62 Matucci (2021120807481525800_cei12858-bib-0008) 2013; 43 Fransen (2021120807481525800_cei12858-bib-0014) 2005; 23 Braun (2021120807481525800_cei12858-bib-0015) 2003; 62 Lewis (2021120807481525800_cei12858-bib-0012) 2008; 14 van Schouwenburg (2021120807481525800_cei12858-bib-0004) 2013; 9 Delluc (2021120807481525800_cei12858-bib-0010) 2011; 25 Vultaggio (2021120807481525800_cei12858-bib-0021) 2012; 159 Mitoma (2021120807481525800_cei12858-bib-0005) 2008; 58 Shankar (2021120807481525800_cei12858-bib-0017) 2008; 48 Boks (2021120807481525800_cei12858-bib-0023) 2014; 151 Arora (2021120807481525800_cei12858-bib-0006) 2009; 45 Vos (2021120807481525800_cei12858-bib-0024) 2011; 140 Vultaggio (2021120807481525800_cei12858-bib-0018) 2010; 65 Bressler (2021120807481525800_cei12858-bib-0002) 2010; 85 Van den Bosch (2021120807481525800_cei12858-bib-0019) 2014; 28 Belostocki (2021120807481525800_cei12858-bib-0027) 2008; 58 Baldwin (2021120807481525800_cei12858-bib-0026) 2010; 69 Siddiqui (2021120807481525800_cei12858-bib-0003) 2005; 65 Mitoma (2021120807481525800_cei12858-bib-0025) 2005; 128 Brown (2021120807481525800_cei12858-bib-0011) 2004; 114 Mukhtyar (2021120807481525800_cei12858-bib-0016) 2009; 68 Willrich (2021120807481525800_cei12858-bib-0001) 2015; 165 Ben-Horin (2021120807481525800_cei12858-bib-0009) 2011; 60 Harvey (2021120807481525800_cei12858-bib-0013) 1980; 1 Maggi (2021120807481525800_cei12858-bib-0020) 2011; 7 Evans (2021120807481525800_cei12858-bib-0022) 2014; 5 Horiuchi (2021120807481525800_cei12858-bib-0007) 2010; 49 21162650 - Expert Rev Clin Immunol. 2011 Jan;7(1):55-63 20194223 - Rheumatology (Oxford). 2010 Jul;49(7):1215-28 22846615 - Int Arch Allergy Immunol. 2012;159(3):321-6 21368101 - FASEB J. 2011 Jun;25(6):2040-8 20436164 - J Rheumatol Suppl. 2010 May;85:40-52 19951375 - Allergy. 2010 May;65(5):657-61 16273792 - Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S93-9 18623174 - Inflamm Bowel Dis. 2008 Dec;14(12):1660-6 12922952 - Ann Rheum Dis. 2003 Sep;62(9):817-24 15316518 - J Allergy Clin Immunol. 2004 Aug;114(2):371-6 18240208 - Arthritis Rheum. 2008 Feb;58(2):384-8 23711128 - Clin Exp Allergy. 2013 Jun;43(6):659-64 15685549 - Gastroenterology. 2005 Feb;128(2):376-92 25305470 - Transl Res. 2015 Feb;165(2):270-82 19054820 - Ann Rheum Dis. 2009 Dec;68(12):1827-32 24568737 - Clin Immunol. 2014 Apr;151(2):136-45 18993008 - J Pharm Biomed Anal. 2008 Dec 15;48(5):1267-81 23399692 - Nat Rev Rheumatol. 2013 Mar;9(3):164-72 6102236 - Lancet. 1980 Mar 8;1(8167):514 25488787 - Best Pract Res Clin Rheumatol. 2014 Oct;28(5):819-27 19773288 - Ann Rheum Dis. 2010 Jun;69(6):1200-7 16225377 - Drugs. 2005;65(15):2179-208 24492460 - Nat Commun. 2014;5:3199 18438840 - Arthritis Rheum. 2008 May;58(5):1248-57 20955706 - Gastroenterology. 2011 Jan;140(1):221-30 20519742 - Gut. 2011 Jan;60(1):41-8 19128982 - Cytokine. 2009 Feb;45(2):124-31 |
| References_xml | – volume: 62 start-page: 817 year: 2003 end-page: 24 article-title: International ASAS consensus statement for the use of anti‐tumour necrosis factor agents in patients with ankylosing spondylitis publication-title: Ann Rheum Dis – volume: 45 start-page: 124 year: 2009 end-page: 31 article-title: Differences in binding and effector functions between classes of TNF antagonists publication-title: Cytokine – volume: 140 start-page: 221 year: 2011 end-page: 30 article-title: Anti‐tumor necrosis factor‐α antibodies induce regulatory macrophages in an Fc region‐dependent manner publication-title: Gastroenterology – volume: 5 start-page: 3199 year: 2014 article-title: TNF‐α blockade induces IL‐10 expression in human CD4+ T cells publication-title: Nat Commun – volume: 43 start-page: 659 year: 2013 end-page: 64 article-title: Allergological and evaluation of patients with hypersensitivity reactions to infliximab publication-title: Clin Exp Allergy – volume: 14 start-page: 1660 year: 2008 end-page: 6 article-title: Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis publication-title: Inflamm Bowel Dis – volume: 85 start-page: 40 year: 2010 end-page: 52 article-title: Optimizing use of tumor necrosis factor inhibitors in the management of immune‐mediated inflammatory diseases publication-title: J Rheumatol Suppl – volume: 1 start-page: 514 year: 1980 article-title: A simple index of Crohn's disease activity publication-title: Lancet – volume: 114 start-page: 371 year: 2004 end-page: 6 article-title: Clinical features and severity grading of anaphylaxis publication-title: J Allergy Clin Immunol – volume: 165 start-page: 270 year: 2015 end-page: 82 article-title: Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases publication-title: Transl Res – volume: 151 start-page: 136 year: 2014 end-page: 45 article-title: Inhibition of TNF receptor signaling by anti‐TNFα biologicals primes naïve CD4(+) T cells towards IL‐10(+) T cells with a regulatory phenotype and function publication-title: Clin Immunol – volume: 58 start-page: 1248 year: 2008 end-page: 57 article-title: Mechanisms for cytotoxic effects of anti‐tumor necrosis factor agents on transmembrane tumor necrosis factor alpha‐expressing cells: comparison among infliximab, etanercept, and adalimumab publication-title: Arthritis Rheum – volume: 159 start-page: 321 year: 2012 end-page: 6 article-title: Drug‐specific Th2 cells and IgE antibodies in a patient with anaphylaxis to rituximab publication-title: Int Arch Allergy Immunol – volume: 48 start-page: 1267 year: 2008 end-page: 81 article-title: Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products publication-title: J Pharm Biomed Anal – volume: 69 start-page: 1200 year: 2010 end-page: 7 article-title: Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis publication-title: Ann Rheum Dis – volume: 128 start-page: 376 year: 2005 end-page: 92 article-title: Infliximab induces potent anti‐inflammatory responses by outside‐to‐inside signals through transmembrane TNF‐alpha publication-title: Gastroenterology – volume: 65 start-page: 657 year: 2010 end-page: 61 article-title: Anti‐infliximab IgE and non‐IgE antibodies and induction of infusion‐related severe anaphylactic reactions publication-title: Allergy – volume: 7 start-page: 55 year: 2011 end-page: 63 article-title: Acute infusion reactions induced by monoclonal antibody therapy publication-title: Expert Rev Clin Immunol – volume: 25 start-page: 2040 year: 2011 end-page: 8 article-title: Quantitative analysis of the CD4 T‐cell repertoire specific to therapeutic antibodies in healthy donors publication-title: FASEB J – volume: 28 start-page: 819 year: 2014 end-page: 27 article-title: Treatment of spondyloarthritis beyond TNF‐alpha blockade publication-title: Best Pract Res Clin Rheumatol – volume: 23 start-page: S93 year: 2005 end-page: 9 article-title: The Disease Activity Score and the EULAR response criteria publication-title: Clin Exp Rheumatol – volume: 49 start-page: 1215 year: 2010 end-page: 8 article-title: Transmembrane TNF‐alpha: structure, function and interaction with anti‐TNF agents publication-title: Rheumatology (Oxf) – volume: 58 start-page: 384 year: 2008 end-page: 8 article-title: Infliximab treatment shifts the balance between stimulatory and inhibitory Fcgamma receptor type II isoforms on neutrophils in patients with rheumatoid arthritis publication-title: Arthritis Rheum – volume: 68 start-page: 1827 year: 2009 end-page: 32 article-title: Modification and validation of the Birmingham Vasculitis Activity Score (version 3) publication-title: Ann Rheum Dis – volume: 9 start-page: 164 year: 2013 end-page: 72 article-title: Immunogenicity of anti‐TNF biologic therapies for rheumatoid arthritis publication-title: Nat Rev Rheumatol – volume: 65 start-page: 2179 year: 2005 end-page: 88 article-title: Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis publication-title: Drugs – volume: 60 start-page: 41 year: 2011 end-page: 8 article-title: The immunogenic part of infliximab is the F(ab)2, but measuring antibodies to the intact infliximab molecule is more clinically useful publication-title: Gut – volume: 140 start-page: 221 year: 2011 ident: 2021120807481525800_cei12858-bib-0024 article-title: Anti-tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner publication-title: Gastroenterology doi: 10.1053/j.gastro.2010.10.008 – volume: 9 start-page: 164 year: 2013 ident: 2021120807481525800_cei12858-bib-0004 article-title: Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis publication-title: Nat Rev Rheumatol doi: 10.1038/nrrheum.2013.4 – volume: 49 start-page: 1215 year: 2010 ident: 2021120807481525800_cei12858-bib-0007 article-title: Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents publication-title: Rheumatology (Oxf) doi: 10.1093/rheumatology/keq031 – volume: 28 start-page: 819 year: 2014 ident: 2021120807481525800_cei12858-bib-0019 article-title: Treatment of spondyloarthritis beyond TNF-alpha blockade publication-title: Best Pract Res Clin Rheumatol doi: 10.1016/j.berh.2014.10.019 – volume: 60 start-page: 41 year: 2011 ident: 2021120807481525800_cei12858-bib-0009 article-title: The immunogenic part of infliximab is the F(ab)2, but measuring antibodies to the intact infliximab molecule is more clinically useful publication-title: Gut doi: 10.1136/gut.2009.201533 – volume: 23 start-page: S93 year: 2005 ident: 2021120807481525800_cei12858-bib-0014 article-title: The Disease Activity Score and the EULAR response criteria publication-title: Clin Exp Rheumatol – volume: 43 start-page: 659 year: 2013 ident: 2021120807481525800_cei12858-bib-0008 article-title: Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab publication-title: Clin Exp Allergy doi: 10.1111/cea.12098 – volume: 65 start-page: 2179 year: 2005 ident: 2021120807481525800_cei12858-bib-0003 article-title: Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis publication-title: Drugs doi: 10.2165/00003495-200565150-00014 – volume: 1 start-page: 514 year: 1980 ident: 2021120807481525800_cei12858-bib-0013 article-title: A simple index of Crohn's disease activity publication-title: Lancet doi: 10.1016/S0140-6736(80)92767-1 – volume: 159 start-page: 321 year: 2012 ident: 2021120807481525800_cei12858-bib-0021 article-title: Drug-specific Th2 cells and IgE antibodies in a patient with anaphylaxis to rituximab publication-title: Int Arch Allergy Immunol doi: 10.1159/000336839 – volume: 85 start-page: 40 year: 2010 ident: 2021120807481525800_cei12858-bib-0002 article-title: Optimizing use of tumor necrosis factor inhibitors in the management of immune-mediated inflammatory diseases publication-title: J Rheumatol Suppl doi: 10.3899/jrheum.091464 – volume: 69 start-page: 1200 year: 2010 ident: 2021120807481525800_cei12858-bib-0026 article-title: Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis publication-title: Ann Rheum Dis doi: 10.1136/ard.2009.110502 – volume: 114 start-page: 371 year: 2004 ident: 2021120807481525800_cei12858-bib-0011 article-title: Clinical features and severity grading of anaphylaxis publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2004.04.029 – volume: 48 start-page: 1267 year: 2008 ident: 2021120807481525800_cei12858-bib-0017 article-title: Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products publication-title: J Pharm Biomed Anal doi: 10.1016/j.jpba.2008.09.020 – volume: 14 start-page: 1660 year: 2008 ident: 2021120807481525800_cei12858-bib-0012 article-title: Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis publication-title: Inflamm Bowel Dis doi: 10.1002/ibd.20520 – volume: 45 start-page: 124 year: 2009 ident: 2021120807481525800_cei12858-bib-0006 article-title: Differences in binding and effector functions between classes of TNF antagonists publication-title: Cytokine doi: 10.1016/j.cyto.2008.11.008 – volume: 7 start-page: 55 year: 2011 ident: 2021120807481525800_cei12858-bib-0020 article-title: Acute infusion reactions induced by monoclonal antibody therapy publication-title: Expert Rev Clin Immunol doi: 10.1586/eci.10.90 – volume: 58 start-page: 384 year: 2008 ident: 2021120807481525800_cei12858-bib-0027 article-title: Infliximab treatment shifts the balance between stimulatory and inhibitory Fcgamma receptor type II isoforms on neutrophils in patients with rheumatoid arthritis publication-title: Arthritis Rheum doi: 10.1002/art.23200 – volume: 151 start-page: 136 year: 2014 ident: 2021120807481525800_cei12858-bib-0023 article-title: Inhibition of TNF receptor signaling by anti-TNFα biologicals primes naïve CD4(+) T cells towards IL-10(+) T cells with a regulatory phenotype and function publication-title: Clin Immunol doi: 10.1016/j.clim.2014.02.008 – volume: 165 start-page: 270 year: 2015 ident: 2021120807481525800_cei12858-bib-0001 article-title: Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases publication-title: Transl Res doi: 10.1016/j.trsl.2014.09.006 – volume: 62 start-page: 817 year: 2003 ident: 2021120807481525800_cei12858-bib-0015 article-title: International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis publication-title: Ann Rheum Dis doi: 10.1136/ard.62.9.817 – volume: 65 start-page: 657 year: 2010 ident: 2021120807481525800_cei12858-bib-0018 article-title: Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions publication-title: Allergy doi: 10.1111/j.1398-9995.2009.02280.x – volume: 128 start-page: 376 year: 2005 ident: 2021120807481525800_cei12858-bib-0025 article-title: Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha publication-title: Gastroenterology doi: 10.1053/j.gastro.2004.11.060 – volume: 25 start-page: 2040 year: 2011 ident: 2021120807481525800_cei12858-bib-0010 article-title: Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors publication-title: FASEB J doi: 10.1096/fj.10-173872 – volume: 68 start-page: 1827 year: 2009 ident: 2021120807481525800_cei12858-bib-0016 article-title: Modification and validation of the Birmingham Vasculitis Activity Score (version 3) publication-title: Ann Rheum Dis doi: 10.1136/ard.2008.101279 – volume: 5 start-page: 3199 year: 2014 ident: 2021120807481525800_cei12858-bib-0022 article-title: TNF-α blockade induces IL-10 expression in human CD4+ T cells publication-title: Nat Commun doi: 10.1038/ncomms4199 – volume: 58 start-page: 1248 year: 2008 ident: 2021120807481525800_cei12858-bib-0005 article-title: Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab publication-title: Arthritis Rheum doi: 10.1002/art.23447 – reference: 19951375 - Allergy. 2010 May;65(5):657-61 – reference: 22846615 - Int Arch Allergy Immunol. 2012;159(3):321-6 – reference: 20436164 - J Rheumatol Suppl. 2010 May;85:40-52 – reference: 19773288 - Ann Rheum Dis. 2010 Jun;69(6):1200-7 – reference: 16273792 - Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S93-9 – reference: 25488787 - Best Pract Res Clin Rheumatol. 2014 Oct;28(5):819-27 – reference: 18993008 - J Pharm Biomed Anal. 2008 Dec 15;48(5):1267-81 – reference: 19054820 - Ann Rheum Dis. 2009 Dec;68(12):1827-32 – reference: 20519742 - Gut. 2011 Jan;60(1):41-8 – reference: 12922952 - Ann Rheum Dis. 2003 Sep;62(9):817-24 – reference: 18438840 - Arthritis Rheum. 2008 May;58(5):1248-57 – reference: 24568737 - Clin Immunol. 2014 Apr;151(2):136-45 – reference: 21162650 - Expert Rev Clin Immunol. 2011 Jan;7(1):55-63 – reference: 20194223 - Rheumatology (Oxford). 2010 Jul;49(7):1215-28 – reference: 24492460 - Nat Commun. 2014;5:3199 – reference: 18623174 - Inflamm Bowel Dis. 2008 Dec;14(12):1660-6 – reference: 23399692 - Nat Rev Rheumatol. 2013 Mar;9(3):164-72 – reference: 16225377 - Drugs. 2005;65(15):2179-208 – reference: 21368101 - FASEB J. 2011 Jun;25(6):2040-8 – reference: 18240208 - Arthritis Rheum. 2008 Feb;58(2):384-8 – reference: 25305470 - Transl Res. 2015 Feb;165(2):270-82 – reference: 6102236 - Lancet. 1980 Mar 8;1(8167):514 – reference: 15316518 - J Allergy Clin Immunol. 2004 Aug;114(2):371-6 – reference: 20955706 - Gastroenterology. 2011 Jan;140(1):221-30 – reference: 23711128 - Clin Exp Allergy. 2013 Jun;43(6):659-64 – reference: 15685549 - Gastroenterology. 2005 Feb;128(2):376-92 – reference: 19128982 - Cytokine. 2009 Feb;45(2):124-31 |
| SSID | ssj0006662 |
| Score | 2.3522496 |
| Snippet | Summary
Antibodies recognizing infliximab (IFX) may develop in a proportion of treated patients, leading to loss of response or hypersensitivity reactions... Antibodies recognizing infliximab (IFX) may develop in a proportion of treated patients, leading to loss of response or hypersensitivity reactions (HRs). T... Summary Antibodies recognizing infliximab (IFX) may develop in a proportion of treated patients, leading to loss of response or hypersensitivity reactions... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 364 |
| SubjectTerms | Adult Aged allergy Antirheumatic Agents - adverse effects arthritis Cell growth Cytokines Cytokines - metabolism Drug Hypersensitivity - blood Drug Hypersensitivity - immunology Female Humans Immune System Diseases - complications Immune System Diseases - drug therapy Immune System Diseases - immunology Immunoglobulin E - immunology Immunoglobulins Infliximab - adverse effects Infliximab - therapeutic use Isoantibodies - blood Isoantibodies - immunology Lymphocyte Activation - immunology Lymphocyte Count Lymphocytes Male Middle Aged Original T cells T-Lymphocyte Subsets - immunology T-Lymphocyte Subsets - metabolism |
| Title | Circulating T cells to infliximab are detectable mainly in treated patients developing anti‐drug antibodies and hypersensitivity reactions |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcei.12858 https://www.ncbi.nlm.nih.gov/pubmed/27569750 https://www.proquest.com/docview/1837401874 https://www.proquest.com/docview/1835680958 https://www.proquest.com/docview/1846417623 https://pubmed.ncbi.nlm.nih.gov/PMC5108070 |
| Volume | 186 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9VQEB5qRXHjo76i9XIUF93kksfJi67aay9VqIi00IUQzis22OZKci9YV_6ALvob-0ucOXm016qIuwOZhORkHt8kM98AvA4ynoWeCDA3iYXL_cR3JZfcNUWBwcdgTA2oOXnvfbx7wN8dRocrsNn3wrT8EMMHN7IM66_JwIVsrhi5MuUYnWtEjb5Uq0WA6OMldRTC8qCfooYhkXesQlTFM5y5HIuuAczrdZJX8asNQNN78Km_9bbu5Mt4MZdj9f0XVsf_fLb7cLcDpmyr1aQHsGKqNbjVjqo8XYPbe91P-IdwNilrZad-VZ_ZPqNP_w2bz1hJDSbfyhMhmagN04b-T1BnFjsRZXV8igLM1rUbzTo614ZdNm0xfMflxY9zXS_atZxRhSMuNTvCbLluqNa-HXbB8DK2IaN5BAfTnf3JrtsNdXAVx9TGNSIUoV9oLcNMxMrPjPJFGGUSMyevSBQCmEKJIg5STxRFxpXHuVaYhooEZSITPobValaZp8DQ-Rj0kamvlOKB8aX2ZVhIbVSmPZ2FDmz0rzdXHeM5Dd44zvvMB_c5t_vswKtB9GtL8_E7ofVeR_LO0pscXSINNUwT7sDL4TDaKO2-qMxsYWWiOEUwm_5NhsdoKohGHXjSqt1wJ0TRnyG0cyBZUshBgDjCl49U5ZHlCo-ohjTBMzesvv354fLJzlu7ePbvos_hDuLHuK3uWYfVeb0wLxCjzeUIbgT8wwhubm2_2Z6OrGn-BDTpP0s |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtRAEC2FIJYLS9gMARrEIRePvLQ3iQsaEk0gkwOaSLkgqzcTi8SD7BmJcOIDOPCNfAlV7SUZAghxa8lly25XVb_qrnoF8CLIeBZ6IsDYJBYu9xPflVxy1xQFLj4G19SAipOn-_HkgL85jA7X4GVfC9PyQwwbbmQZ1l-TgdOG9DkrV6YcoXeN0ktwmTp6E3P-63dn5FEIzIO-jxouirzjFaI8nuHW1dXoAsS8mCl5HsHaJWjnJrzvX77NPPk4Wi7kSH35hdfxf7_uFtzosCl71SrTbVgz1QZcabtVnm7A1Wl3Dn8Hvo3LWtnGX9UHNmO0-9-wxZyVVGPyuTwRkonaMG3oiIKKs9iJKKvjUxRgNrXdaNYxujbsrG6L4W8uf3z9rutlO5ZzSnLEoWZHGDDXDaXbt_0uGD7G1mQ0d-FgZ3s2nrhdXwdXcYxuXCNCEfqF1jLMRKz8zChfhFEmMXjyikQhhimUKOIg9URRZFx5nGuFkahIUCYy4T1Yr-aVeQAM_Y9BN5n6SikeGF9qX4aF1EZl2tNZ6MBW_39z1ZGeU--N47wPfnCeczvPDjwfRD-1TB-_E9rslSTvjL3J0StSX8M04Q48Gy6jmdLsi8rMl1YmilPEs-nfZHiM1oKA1IH7rd4Nb0Is_RmiOweSFY0cBIgmfPVKVR5ZuvCI0kgTvHPLKtyfPy4fb-_awcN_F30K1yaz6V6-t7v_9hFcRzgZt8k-m7C-qJfmMUK2hXxiLfMnZn5BHg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1JTxVBEK4gRuLFIG4jqK3xwGXMLD1bPJkHL6BCOEDCbdIrTALzyMx7idz8AR78jf4SqnoWeUGNt06mejLT1VX1VXctAO-jghdxICL0TVLh8zALfckl9421aHwM2tSIkpMPDtO9E_75NDldgY9DLkxXH2I8cCPJcPqaBPxK21tCrkz1AZVrkt-D-3TZR_FcET8a1TDi8mhoo4Y2kfdlhSiMZ5y6bIzuIMy7gZK3AayzQNN1eNRDR_ap4_VjWDH1Bjzomkleb8DaQX9N_gR-TKpGub5c9Rk7ZnQ437L5jFWUAvKtuhSSicYwbegGgXKn2KWo6otrJGAu8txo1hdcbdnvtCqGXKh-ff-pm0U3ljOKQcShZufozzYtRcN37SgYvsalTLRP4WS6ezzZ8_u2C77i6Hz4RsQiDq3WMi5EqsLCqFDESSHRtwlsphBiWCVsGuWBsLbgKuBcK3QURYY0iYmfwWo9q80LYKgeDGqxPFRK8ciEUocytlIbVehAF7EH28P6l6qvSU6tMS7KwTdBVpWOVR68G0mvukIcfyLaGphY9rLYlqi0qO1gnnEP3o6PUYpo9UVtZgtHk6Q5ws38XzQ8xc2MeNGD592-GL-EiugXCL48yJZ2zEhAVbyXn9TVuavmnVCUZ4Yzt93e-vvPlZPdfTd4-f-kb2DtaGdaft0__LIJDxHspV0ozhaszpuFeYWAai5fO8G5AXxoH6I |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Circulating+T+cells+to+infliximab+are+detectable+mainly+in+treated+patients+developing+anti%E2%80%90drug+antibodies+and+hypersensitivity+reactions&rft.jtitle=Clinical+and+experimental+immunology&rft.au=Vultaggio%2C+A.&rft.au=Petroni%2C+G.&rft.au=Pratesi%2C+S.&rft.au=Nencini%2C+F.&rft.date=2016-12-01&rft.issn=0009-9104&rft.eissn=1365-2249&rft.volume=186&rft.issue=3&rft.spage=364&rft.epage=372&rft_id=info:doi/10.1111%2Fcei.12858&rft.externalDBID=10.1111%252Fcei.12858&rft.externalDocID=CEI12858 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-9104&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-9104&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-9104&client=summon |